Abstract

The Vector Core is a critical resource to members of the Institute for Human Gene Therapy providing access to a wide array of gene transfer technology. This dedicated facility is run by Dr. Alan Davis, who has extensive academic and industry based experience in recombinant viruses. The Core has assembled a comprehensive inventory of plasmids, cell lines, and viruses useful to the development of vectors. More comprehensive service is provided in the design, creation, production, and analysis of recombinant viruses. A number of vector systems are available through the Core, including murine-based retroviruses, adenoviruses, and adeno- associated viruses (AAV). The Vector Core maintains strong links to key laboratories in the Institute for Human Gene Therapy involved in novel vector development. Relevant innovations are quickly brought into the Vector Core, where they are validated and distributed to faculty. The initial forces of the Vector Core was on murine based retroviruses. In the early 1990's, recombinant adenoviruses were brought into the Core and have dominated its activity until two years ago when AAV took center stage. Improved methods of production and analysis of AAV are being developed in the Institute for applications within the Vector Core. The participants of this P30 will utilize the full range of services available from the Vector Core.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK047757-08
Application #
6358014
Study Section
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$191,831
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Svidritskiy, Egor; Korostelev, Andrei A (2018) Mechanism of Inhibition of Translation Termination by Blasticidin S. J Mol Biol 430:591-593
Svidritskiy, Egor; Korostelev, Andrei A (2018) Conformational Control of Translation Termination on the 70S Ribosome. Structure 26:821-828.e3
Gurda, Brittney L; De Guilhem De Lataillade, Adrien; Bell, Peter et al. (2016) Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther 24:206-216
Svidritskiy, Egor; Madireddy, Rohini; Korostelev, Andrei A (2016) Structural Basis for Translation Termination on a Pseudouridylated Stop Codon. J Mol Biol 428:2228-36
Greig, Jenny A; Calcedo, Roberto; Grant, Rebecca L et al. (2016) Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 34:6323-6329
McClain, Lauren E; Davey, Marcus G; Zoltick, Phillip W et al. (2016) Vector serotype screening for use in ovine perinatal lung gene therapy. J Pediatr Surg 51:879-84
Calcedo, Roberto; Wilson, James M (2016) AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum Gene Ther Clin Dev 27:79-82
Svidritskiy, Egor; Korostelev, Andrei A (2015) Ribosome Structure Reveals Preservation of Active Sites in the Presence of a P-Site Wobble Mismatch. Structure 23:2155-61
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Calcedo, Roberto; Franco, Judith; Qin, Qiuyue et al. (2015) Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods 26:103-5

Showing the most recent 10 out of 231 publications